Viracta Therapeutics (VIRX) Competitors $0.16 +0.01 (+6.64%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VIRX vs. LSB, CLDI, LSTA, XCUR, CVKD, FBRX, CMMB, IBIO, TPST, and PULMShould you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Lakeshore Biopharma (LSB), Calidi Biotherapeutics (CLDI), Lisata Therapeutics (LSTA), Exicure (XCUR), Cadrenal Therapeutics (CVKD), Forte Biosciences (FBRX), Chemomab Therapeutics (CMMB), iBio (IBIO), Tempest Therapeutics (TPST), and Pulmatrix (PULM). These companies are all part of the "pharmaceutical products" industry. Viracta Therapeutics vs. Lakeshore Biopharma Calidi Biotherapeutics Lisata Therapeutics Exicure Cadrenal Therapeutics Forte Biosciences Chemomab Therapeutics iBio Tempest Therapeutics Pulmatrix Lakeshore Biopharma (NASDAQ:LSB) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment. Is LSB or VIRX more profitable? Lakeshore Biopharma's return on equity of 0.00% beat Viracta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lakeshore BiopharmaN/A N/A N/A Viracta Therapeutics N/A -1,899.61%-114.21% Which has more risk and volatility, LSB or VIRX? Lakeshore Biopharma has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Which has stronger valuation & earnings, LSB or VIRX? Viracta Therapeutics has lower revenue, but higher earnings than Lakeshore Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLakeshore Biopharma$80.82M0.30-$61.09MN/AN/AViracta TherapeuticsN/AN/A-$51.06M-$1.10-0.15 Does the MarketBeat Community believe in LSB or VIRX? Viracta Therapeutics received 29 more outperform votes than Lakeshore Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformLakeshore BiopharmaN/AN/AViracta TherapeuticsOutperform Votes2972.50% Underperform Votes1127.50% Do analysts prefer LSB or VIRX? Viracta Therapeutics has a consensus price target of $5.00, indicating a potential upside of 3,011.39%. Given Viracta Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viracta Therapeutics is more favorable than Lakeshore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lakeshore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Viracta Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media prefer LSB or VIRX? In the previous week, Viracta Therapeutics had 4 more articles in the media than Lakeshore Biopharma. MarketBeat recorded 5 mentions for Viracta Therapeutics and 1 mentions for Lakeshore Biopharma. Lakeshore Biopharma's average media sentiment score of 0.00 beat Viracta Therapeutics' score of -1.00 indicating that Lakeshore Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lakeshore Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viracta Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Do insiders and institutionals have more ownership in LSB or VIRX? 52.6% of Lakeshore Biopharma shares are owned by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are owned by institutional investors. 10.7% of Viracta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryViracta Therapeutics beats Lakeshore Biopharma on 7 of the 12 factors compared between the two stocks. Ad Paradigm Press[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.Click here now for the urgent details on this hidden play. Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRX vs. The Competition Export to ExcelMetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.39M$6.59B$5.21B$8.85BDividend YieldN/A8.14%5.53%4.08%P/E Ratio-0.155.9576.4514.80Price / SalesN/A357.081,246.7887.32Price / CashN/A53.8240.9036.92Price / Book-0.9510.617.196.55Net Income-$51.06M$153.27M$119.54M$226.22M7 Day Performance6.42%3.97%2.12%3.77%1 Month Performance-33.87%-6.72%-2.43%4.64%1 Year Performance-69.16%33.26%34.52%29.21% Viracta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRXViracta Therapeutics1.4928 of 5 stars$0.16+6.6%$5.00+3,011.4%-69.2%$6.39MN/A-0.1520Negative NewsLSBLakeshore Biopharma0.2257 of 5 stars$2.57-1.9%N/AN/A$23.93M$80.82M0.00773CLDICalidi Biotherapeutics2.5661 of 5 stars$2.15-6.1%$16.67+675.2%N/A$23.89M$50,000.000.0041High Trading VolumeLSTALisata Therapeutics3.3471 of 5 stars$2.84-3.1%$15.00+428.2%+25.2%$23.83MN/A-1.1330Analyst ForecastAnalyst RevisionPositive NewsXCURExicure1.7772 of 5 stars$10.86-2.9%N/A+3,576.0%$23.57M$28.83M-5.2550Gap UpCVKDCadrenal Therapeutics1.6839 of 5 stars$14.01-3.4%$18.00+28.5%N/A$23.26MN/A-2.104Analyst RevisionFBRXForte Biosciences3.9861 of 5 stars$15.55+14.8%$23.58+51.7%+91,161.7%$22.70MN/A-0.955Insider TradeNews CoverageGap DownHigh Trading VolumeCMMBChemomab Therapeutics2.8183 of 5 stars$1.58-3.7%$7.33+364.1%+197.3%$22.69MN/A-1.5820IBIOiBio0.8638 of 5 stars$2.45+11.9%$4.30+75.5%N/A$22.42M$220,000.000.00100TPSTTempest Therapeutics2.2871 of 5 stars$0.89-1.1%$20.00+2,157.6%-78.4%$22.33MN/A-0.5920PULMPulmatrix0.2893 of 5 stars$6.10+8.5%N/A+230.8%$22.27M$7.30M-2.3120High Trading Volume Related Companies and Tools Related Companies LSB Alternatives CLDI Alternatives LSTA Alternatives XCUR Alternatives CVKD Alternatives FBRX Alternatives CMMB Alternatives IBIO Alternatives TPST Alternatives PULM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VIRX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
